These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 22005217

  • 1. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L, Denaro A, Agustoni F, Bajetta E.
    J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
    [Abstract] [Full Text] [Related]

  • 2. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 3. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E, Astara G, Madeddu C, Dessì M, Loi C, Lepori S, Mantovani G.
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [Abstract] [Full Text] [Related]

  • 4. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

  • 5. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [Abstract] [Full Text] [Related]

  • 6. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 8. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
    Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS.
    Support Care Cancer; 2013 Feb; 21(2):565-73. PubMed ID: 22869054
    [Abstract] [Full Text] [Related]

  • 9. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003 Feb; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 10. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [Abstract] [Full Text] [Related]

  • 12. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
    Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E, Italian Trials in Medical Oncology Group.
    Support Care Cancer; 2011 Aug; 19(8):1217-25. PubMed ID: 20574663
    [Abstract] [Full Text] [Related]

  • 13. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C, Gayle J, Balu S, Buchner D.
    J Med Econ; 2011 Aug; 14(3):341-9. PubMed ID: 21542674
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D.
    Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
    [Abstract] [Full Text] [Related]

  • 15. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM.
    Cancer; 2009 Dec 15; 115(24):5807-16. PubMed ID: 19834961
    [Abstract] [Full Text] [Related]

  • 16. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Herrington JD, Jaskiewicz AD, Song J.
    Cancer; 2008 May 01; 112(9):2080-7. PubMed ID: 18327813
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.
    Support Care Cancer; 2009 May 01; 17(5):589-94. PubMed ID: 19037667
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V.
    J Support Oncol; 2006 Sep 01; 4(8):403-8. PubMed ID: 17004515
    [Abstract] [Full Text] [Related]

  • 19. Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.
    Rigacci L, Landi C, Caruso JP, Puccini B, Alterini R, Carrai V, Perrone T, Bosi A.
    Leuk Res; 2012 Feb 01; 36(2):182-5. PubMed ID: 21752467
    [Abstract] [Full Text] [Related]

  • 20. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.